NFINITT North America, a leader in advanced healthcare imaging solutions, is excited to announce the newest addition to its digital pathology platform: the FDA-cleared Hamamatsu NanoZoomer S360MD Slide Scanner, now seamlessly integrated with the INFINITT Digital Pathology Solution (DPS). This milestone solidifies INFINITT’s position among the digital pathology sector’s top innovators and signals a new era of practical, flexible imaging for U.S. hospitals and labs.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
The INFINITT Digital Pathology Solution, FDA-cleared for primary diagnosis of FFPE tissue slides, now supports Hamamatsu NDPI file format through its collaboration. Facilities can leverage existing slide archives and hardware investments; lowering adoption barriers and accelerating the switch to a fully digital workflow—all within current hospital infrastructure.
Health Technology Insights: Norgine Expands Liver and Specialty Portfolio With Vir Biotechnology In-Licensing Agreement
“This FDA clearance reflects our commitment to helping institutions across the country move forward with digital pathology—not just as a buzzword, but as an actionable, interoperable reality,” said David Smarro, CEO for INFINITT North America. “By making leading-edge technology truly accessible, we’re powering smarter, faster, and more connected patient care.”
“This FDA clearance reflects our commitment to helping institutions across the country move forward with digital pathology—not just as a buzzword, but as an actionable, interoperable reality,” said David Smarro, CEO for INFINITT North America.
Poised for Continued Growth and Innovation
INFINITT isn’t just a digital pathology company. With established excellence in radiology, cardiology, ophthalmology, dental imaging, and more, the organization is positioned as a comprehensive imaging partner for healthcare leaders nationwide. The recent FDA clearance is just another step in our comprehensive plan. We’re actively developing support for additional scanners and plan to submit these for FDA review in 2026.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Web
